Log In
Print
BCIQ
Print
Print this Print this
 

Omontys, peginesatide (formerly Hematide)

  Manage Alerts
Collapse Summary General Information
Company Affymax Inc.
DescriptionSynthetic peptide-based erythropoiesis-stimulating agent (ESA)
Molecular Target Erythropoietin (EPO) receptor
Mechanism of ActionErythropoietin (EPO) receptor agonist
Therapeutic ModalityPeptide
Latest Stage of DevelopmentMarketed
Standard IndicationAnemia
Indication DetailsTreat anemia due to chronic kidney disease (CKD) in adult patients on dialysis; Treat anemia in chronic kidney disease (CKD) patients with pure red cell aplasia (PRCA); Treat chemotherapy-induced anemia (CIA)
Regulatory Designation

Partner

Takeda Pharmaceutical Co. Ltd.


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today